Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a leading medical device company dedicated to developing innovative solutions for the interventional treatment of vascular thrombi and emboli. The company's mission centers on improving the lives of patients suffering from venous and other related diseases through the design and production of advanced medical devices.
Inari Medical's product portfolio includes several key devices:
- ClotTriever: Designed for the removal of clots from peripheral blood vessels, primarily treating patients with deep vein thrombosis (DVT).
- FlowTriever System: Used for the treatment of pulmonary embolism (PE).
- InThrill System: Aimed at treating small vessel thrombosis.
- LimFlow System: Another innovative solution recently added to their portfolio through acquisition.
The company operates extensively within the United States but also generates significant revenue from international markets. Inari Medical's dedication to clinical research and patient education is evident in their continuous efforts to generate high-quality clinical data to support their products.
In recent news, Inari Medical announced the PEERLESS II RCT, a major clinical study involving up to 1,200 patients. This study aims to influence global guidelines for treating intermediate-risk PE patients. Inari's fourth-quarter financial results showed a substantial revenue increase, driven by the strong adoption of their procedures, new product launches, and global commercial expansion. The company reported $132.1 million in revenue for Q4 2023, marking a 22.6% increase year-over-year.
Additionally, Inari Medical has undertaken significant legal action to protect its intellectual property. The company filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc., seeking injunctive relief and damages for infringement on eight of its patents.
Guided by principles such as putting patients first and fostering innovation, Inari Medical continues to advance its mission of establishing its treatments as the standard of care for venous thromboembolism and beyond.
Inari Medical, Inc. (NARI) reported first-quarter 2021 revenue of $57.4 million, a significant 113% increase compared to the same period last year and an 18% sequential growth. The company treated a record number of patients and enrolled the first patient in the FLAME study, a pivotal clinical trial for high-risk pulmonary embolism patients. Operating expenses rose to $45.1 million, largely due to increased personnel costs. Net income was $7.5 million, with an EPS of $0.15. The company forecasts 2021 revenue between $240 million to $250 million.
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in the 2021 Bank of America Healthcare Conference on May 13, 2021, at 8:45 a.m. ET. This commercial-stage medical device company focuses on innovative products for venous diseases. Inari has developed two FDA-cleared devices: the ClotTriever for deep vein thrombosis and the FlowTriever for pulmonary embolism. Both systems are designed to effectively remove large clots without the need for thrombolytic drugs, enhancing patient outcomes in treating venous thromboembolism.
Inari Medical (NASDAQ: NARI) announced its financial results for Q1 2021 will be released on May 11, 2021. A conference call and webcast will occur the same day at 1:30 PM PT / 4:30 PM ET to discuss the results and recent highlights. Inari is a commercial-stage medical device company focused on innovative treatments for venous diseases. Its key products include the ClotTriever and FlowTriever systems, both FDA cleared and CE Mark approved for treating deep vein thrombosis and pulmonary embolism.
Inari Medical, Inc. (NASDAQ: NARI) has announced a global partnership with Aidoc, an AI solutions provider, to enhance the detection and treatment of pulmonary embolism (PE). The collaboration aims to integrate AI into clinical pathways, improving patient outcomes by rapidly triaging scans for suspected PE. With recent studies indicating that many high-risk PE patients do not receive timely care, this partnership seeks to leverage technology to optimize treatment pathways. Key executives from both companies highlighted the significance of AI in transforming patient care standards.
Inari Medical, Inc. (NASDAQ: NARI) has enrolled its first high-risk pulmonary embolism (PE) patient in the FLAME study, which aims to evaluate treatment outcomes in up to 250 high-risk PE patients. This multicenter observational study, the largest of its kind, seeks to change treatment guidelines by examining patients treated with FlowTriever and those managed conservatively. Additionally, Inari is expanding the FLASH study to 1,000 patients to gather more data and is set to monitor patients using the Apple Watch, emphasizing their commitment to tackling pulmonary embolism with innovative studies.
Inari Medical (NASDAQ: NARI) reported strong Q4 2020 results, with revenue of $48.6 million, a 26% sequential increase, and 144% year-over-year growth. The company treated a record 4,600 patients, reflecting a 24% sequential rise. Their gross profit reached $44.9 million, with a gross margin of 92.4%. For 2020, total revenue was $139.7 million, up from $51.1 million in 2019, and net income was $13.8 million. Despite COVID-19 challenges, Inari expects Q1 2021 revenue between $54-$56 million and full-year 2021 revenue of $225-$235 million.
Inari Medical, Inc. (NASDAQ: NARI) will announce its fourth quarter and full year 2020 financial results on March 9, 2021, after market close. Following the announcement, a conference call is scheduled at 1:30 p.m. PST / 4:30 p.m. EST to discuss the results and recent highlights. Inari specializes in developing medical devices for venous diseases, with notable products like the ClotTriever and FlowTriever systems, designed for thrombosis treatment. Both systems are FDA cleared and CE Mark approved.
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in two upcoming investor conferences. The BTIG Virtual MedTech Conference will take place on February 17, 2021, at 4:00 p.m. ET, while the SVB Leerink Partners Virtual Global Healthcare Conference is scheduled for February 24, 2021, at 1:00 p.m. ET. Both presentations will be available for live streaming on the company’s Investor Relations webpage. Inari specializes in medical devices for venous disease treatment, with products like the ClotTriever and FlowTriever systems designed for thrombectomy.
Inari Medical, Inc. (NASDAQ: NARI) announced positive interim results from the ClotTriever Outcomes Registry, focusing on 64 chronic DVT patients. The ClotTriever device removed a median of 90% of clots in a single session without thrombolytics, with no serious adverse events reported. The median procedure time was 34 minutes, and the median blood loss was 50cc. Inari's recent CE Mark approval allows for global commercialization, enhancing treatment options for venous disease patients. The company has treated over 20,000 VTE patients, emphasizing the ongoing need for improved therapies.
Inari Medical, Inc. (NASDAQ: NARI) reported preliminary unaudited revenue for Q4 2020, estimating between $47.9 million and $48.9 million, marking a 141% to 146% increase year-over-year and a 24% to 26% rise from Q3 2020. The company performed approximately 4,600 procedures in Q4, up 156% year-over-year and 24% from the prior quarter. The COVID-19 pandemic posed challenges, yet the CEO expressed confidence in strategic execution and upcoming earnings report.
Full financial results will be disclosed in the Annual Report on Form 10-K.
FAQ
What is the current stock price of Inari Medical (NARI)?
What is the market cap of Inari Medical (NARI)?
What does Inari Medical, Inc. specialize in?
What are the key products in Inari Medical's portfolio?
Where does Inari Medical generate most of its revenue?
What recent clinical study has Inari Medical announced?
How did Inari Medical perform financially in the fourth quarter of 2023?
What is Inari Medical's approach to innovation?
Who should investors contact for more information?
What legal actions has Inari Medical recently taken?
What are Inari Medical's guiding principles?
How can interested parties access Inari Medical's live events?
